Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513994 | 0.85 | — | — | |
| SCHEMBL9129884 | 0.85 | — | — | |
| SCHEMBL11103446 | 0.85 | LMNA (0.42) | LMNAALOX15CYP1B1ALDH1A1TSHR | |
| SCHEMBL17632024 | 0.74 | LMNA (0.37) | LMNAALOX15CYP1B1ALDH1A1TSHR | |
| SCHEMBL3934132 | 0.74 | ALDH1A1 (0.38) | LMNAALOX15CYP1B1ALDH1A1TSHR | |
| SCHEMBL13806124 | 0.74 | LMNA (0.37) | LMNAALOX15CYP1B1ALDH1A1TSHR | |
| SCHEMBL774116 | 0.74 | LMNA (0.37) | LMNAALOX15CYP1B1ALDH1A1TSHR | |
| SCHEMBL16259520 | 0.74 | NOS2 (0.30) | — | |
| SCHEMBL6730278 | 0.74 | LMNA (0.37) | LMNAALOX15CYP1B1ALDH1A1TSHR | |
| SCHEMBL16259519 | 0.74 | NOS2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022261210-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2020233677-A1 | PROCESS FOR PREPARING AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS | BEIGENE (BEIJING) CO., LTD. (CN) | 2020-11-26 | — | — | WO | disclosed |
| US-8088763-B2 | e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases | GRUENENTHAL GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| EP-2029529-B1 | SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-07-07 | — | — | EP | disclosed |
| EP-2112151-A2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| US-5889012-A | INSECTICIDE, ACARICIDES, FUNGICIDES | HOECHST-SCHERING AGREVO GMBH (DE) | 1999-03-30 | — | — | US | disclosed |
| EP-0787128-A1 | SUBSTITUTED CYCLOALKYLAMINO AND CYCLOALKOXY HETEROCYCLES, PROCESS FOR PREPARING THE SAME AND THEIR USE AS PESTICIDES | Hoechst Schering AgrEvo GmbH (DE) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996011913-A1 | SUBSTITUTED CYCLOALKYLAMINO AND CYCLOALKOXY HETEROCYCLES, PROCESS FOR PREPARING THE SAME AND THEIR USE AS PESTICIDES | HOECHST SCHERING AGREVO GMBH (DE) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | PKD1, DDC, DPYD | LMNA 1995/4885ALOX15 2058/4885CYP1B1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.